Torrent Pharmaceuticals Ltd. benchmarking: Performance to industry peers

Financial

	Torrent Pharma	Lupin	Dr. Reddy's Lab
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	172.0 .	431.0 .	371.0 .
Number of ANDA's Approved By USFDA	132.0 .	341.0 .	300.0 .
Domestic Sales Growth - YoY	17.2 %	12.8 %	10.1 %
R&D as a % of Total Sales	5.0 %	7.5 %	7.0 %
Financials
5 yr Average ROE	20.79 %	8.95 %	15.68 %
5yr average Equity Multiplier	2.16	1.73	1.41
5yr Average Asset Turnover Ratio	0.69	0.75	0.74
5yr Avg Net Profit Margin	13.95 %	5.06 %	15.18 %
Price to Book	15.98	5.3	2.82
P/E	59.42	22.41	18.25
5yr Avg Cash Conversion Cycle	-186.79 Days	-84.38 Days	74.48 Days
Inventory Days	54.98 Days	53.29 Days	76.14 Days
Days Receivable	40.18 Days	50.0 Days	95.44 Days
Days Payable	298.32 Days	160.27 Days	102.6 Days
5yr Average Interest Coverage Ratio	7.38	6.26	35.66
5yr Avg ROCE	25.78 %	10.02 %	21.82 %
5yr Avg Operating Profit Margin	30.49 %	14.15 %	23.61 %
5 yr average Debt to Equity	0.66	0.3	0.12
5yr CAGR Net Profit	8.83 %	21.95 %	23.71 %
5yr Average Return on Assets	9.73 %	3.91 %	11.24 %
Shareholdings
Promoter Holding	68.31 %	46.89 %	26.64 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-2.94 %	-0.21 %	-0.06 %
Change in Mutual Fund Holding (3 Yrs)	-1.4 %	1.54 %	2.93 %

Business

	Torrent Pharma	Lupin	Dr. Reddy's Lab
Product Wise Break-Up	Product Wise Break-Up Domestic Formulations 42.15 US Formulations 20.71 Germany 13.15 Brazil 8.98 Contract Manufacturing 6.15 USA 0 Developed Markets 0 NCE licensing income 0 API 0 India 0 Emerging Market Formulation 0 Advanced Markets Formulations 0 Generic FDF 0 Custom Synthesis 0 Proprietary Products 0 Global Generics 0 0 Others 8.86	Product Wise Break-Up US Formulations 0 Contract Manufacturing 0 India 34.0 Custom Synthesis 0 Brazil 0 Advanced Markets Formulations 45.0 Proprietary Products 0 Global Generics 0 Germany 0 NCD 1.0 Active Pharmaceutical Ingredient (API) 9.0 Emerging Market 12.0 0 Generic FDF 0 Developed Markets 0 USA 0 Domestic Formulations 0	Product Wise Break-Up US Formulations 0 Contract Manufacturing 0 India 0 Custom Synthesis 0 Brazil 0 Advanced Markets Formulations 0 Proprietary 0.17 Formulations 89.21 Germany 0 NCE licensing income 0 API 0 Emerging Market Formulation 0 Pharmaceutical 10.62 Generic FDF 0 Developed Markets 0 USA 0 Domestic Formulations 0
Location Wise Break-Up	Location Wise Break-Up India 54.44 Brazil 11.23 USA 9.72 Germany 9.2 API 0 EMEA 0 Growth Markets 0 Japan 0 Russia 0 Others 15.41	Location Wise Break-Up India 29.0 EMEA 13.0 Brazil 0 Germany 0 API 3.0 Developed Markets 11.0 Russia 0 USA 44.0 Japan 0	Location Wise Break-Up India 17.36 EMEA 0 Brazil 0 Germany 0 API 0 Growth Markets 0 Russia 7.99 USA 48.56 Japan 0 Others 26.09
Acute vs Chronic	Acute vs Chronic Chronic 76.0 Acute 24.0 Sub - chronic 0	Acute vs Chronic Chronic 63.1 Acute 36.9 Sub - chronic 0	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Cardiac Science 25.0 Gastro Intestinal 17.0 CNS 15.0 VMN 11.0 Anti - Diabetes 10.0 Pain Management 7.0 Gynecology 2.0 Anti-Infective 2.0 Rest 2.0 Respiratory 0 Anti-Infective 0 Central Nervous System 0 Pain Management 0 Cardiovascular 0 Oncology 0 Gastrointestinal 0 Others 9.0	-	Therapeutic Area Break-Up Oncology 27.53 Rest 0 Cardiac Science 0 CNS 0 Gynecology 0 Central Nervous System (CNS) 12.12 Cardiac Science 6.65 Anti-Infective 6.48 Respiratory 7.04 Gastro Intestinal 0 Pain Management 9.77 Gastro Intestinal 9.52 VMN 0 Anti - Diabetes 0 Others 20.89
Asset Break-Up	Asset Break-Up India 94.39 United States 0 Switzerland 0 Others 5.61	-	Asset Break-Up USA 2.37 India 80.24 Switzerland 8.45 Others 8.94

Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

Financial

Business

SIGN UP FOR FREE